These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2875651)

  • 1. The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure.
    Leier CV; Patterson SE; Huss P; Parrish D; Unverferth DV
    Am J Med Sci; 1986 Sep; 292(3):128-35. PubMed ID: 2875651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic effects of terazosin in congestive heart failure.
    Zhu J; Wang D; Lu Z; Liu Z; Yang D
    Chin Med Sci J; 1993 Jun; 8(2):98-100. PubMed ID: 7904837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rest and exercise cardiovascular effects of terazosin in congestive heart failure.
    Magorien RD; Sinnathamby S; Leier CV; Boudoulas H; Unverferth DV
    Am J Cardiol; 1990 Mar; 65(9):638-43. PubMed ID: 1968703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute hemodynamic effects of terazosin in hypertensive and normotensive patients.
    Strom JA; Zola B; Frishman W; Laddu A; Wexler JP; Carlson K; Jordan A
    Am Heart J; 1991 Sep; 122(3 Pt 2):892-900. PubMed ID: 1678919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic responses to indoramin at rest and during exercise in congestive heart failure.
    Leier CV; Majetich N; Binkley PF; Uverferth DV
    Pharmacotherapy; 1987; 7(3):61-8. PubMed ID: 3628063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure.
    Good AP; Unverferth DV; Leier CV
    Cardiovasc Drugs Ther; 1988 Jan; 1(5):529-34. PubMed ID: 2908715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
    Tomoda F; Takata M; Yoshida K; Yasumoto K; Mikawa M; Sasayama S
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):834-9. PubMed ID: 2574044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of prazosin effect on cardiac output in chronic heart failure.
    Arnold SB; Williams RL; Ports TA; Baughman RA; Benet LZ; Parmley WW; Chatterjee K
    Ann Intern Med; 1979 Sep; 91(3):345-9. PubMed ID: 475164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of terazosin.
    Kyncl JJ
    Am J Med; 1986 May; 80(5B):12-9. PubMed ID: 2872801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of pharmacodynamic tolerance to prozosin in congestive heart failure.
    Desch CE; Magorien RD; Triffon DW; Blanford MF; Unverferth DV; Leier CV
    Am J Cardiol; 1979 Nov; 44(6):1178-82. PubMed ID: 495512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.
    Vincent J; Dachman W; Blaschke TF; Hoffman BB
    J Clin Invest; 1992 Nov; 90(5):1763-8. PubMed ID: 1358918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin.
    McNeil JJ; Drummer OH; Conway EL; Workman BS; Louis WJ
    J Cardiovasc Pharmacol; 1987 Aug; 10(2):168-75. PubMed ID: 2441167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute and chronic effects of bunazosin in patients with congestive heart failure].
    Kawahara Y; Hasegawa K; Sawayama T; Nezuo S; Inoue S; Tadaoka S
    Kokyu To Junkan; 1989 May; 37(5):529-33. PubMed ID: 2568669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nifedipine in congestive heart failure: effects on resting and exercise hemodynamics and regional blood flow.
    Leier CV; Patrick TJ; Hermiller J; Pacht KD; Huss P; Magorien RD; Unverferth DV
    Am Heart J; 1984 Dec; 108(6):1461-8. PubMed ID: 6507242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure.
    Kukin ML; Freudenberger RS; Mannino MM; Kalman J; Steinmetz M; Buchholz-Varley C; Ocampo ON
    Am Heart J; 1999 Aug; 138(2 Pt 1):261-8. PubMed ID: 10426837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute hemodynamic and hormonal effects of central versus peripheral sympathetic inhibition in patients with congestive heart failure.
    Olivari MT; Levine TB; Cohn JN
    J Cardiovasc Pharmacol; 1986; 8(5):973-7. PubMed ID: 2429099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
    Stambler BS; Gottlieb SS; Singh BN; Ramanathan KB; Ogilby JD; Ellenbogen KA
    J Am Coll Cardiol; 1995 Dec; 26(7):1679-84. PubMed ID: 7594103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise.
    Bayliss J; Canepa-Anson R; Norell MS; Poole-Wilson P; Sutton G
    Br Heart J; 1986 Mar; 55(3):265-73. PubMed ID: 3513808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.